Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)

被引：0

作者：

Yap, Y. S. ^{[1
]}

Masuda, N. ^{[2
]}

Ito, Y. ^{[3
]}

Ishikawa, T. ^{[4
]}

Kim, S. J. ^{[5
]}

Aruga, T. ^{[6
]}

Toyama, T. ^{[7
]}

Saeki, T. ^{[8
]}

Yamanaka, T. ^{[9
]}

Saito, M. ^{[10
]}

Watanabe, J. ^{[11
]}

Takahashi, M. ^{[12
]}

Nakamura, S. ^{[13
]}

Inoue, K. ^{[14
]}

Suarez-Vizcarra, J. ^{[15
]}

He, W. ^{[15
]}

Solovieff, N. ^{[16
]}

Su, F. ^{[15
]}

Chiu, J. ^{[17
]}

机构：

[1] Natl Canc Ctr, Med Oncol, Singapore, Singapore

[2] Osaka Natl Hosp, Med Oncol, Osaka, Japan

[3] Japanese Fdn Canc Res, Canc Inst Hosp, Med Oncol, Tokyo, Japan

[4] Tokyo Med Univ Hosp, Med Oncol, Tokyo, Japan

[5] Osaka Univ Hosp, Med Oncol, Osaka, Japan

[6] Tokyo Komagome Hosp, Med Oncol, Tokyo, Japan

[7] Nagoya City Univ, Grad Sch Med Sci, Med Oncol, Nagoya, Aichi, Japan

[8] Saitama Med Univ, Med Oncol, Int Med Ctr, Saitama, Japan

[9] Kanagawa Canc Ctr, Med Oncol, Yokohama, Kanagawa, Japan

[10] Juntendo Univ Hosp, Med Oncol, Tokyo, Japan

[11] Shizuoka Canc Ctr, Med Oncol, Nagaizumi, Shizuoka, Japan

[12] Hokkaido Canc Ctr, Natl Hosp Org, Med Oncol, Sapporo, Hokkaido, Japan

[13] Showa Univ Hosp, Breast Ctr, Tokyo, Japan

[14] Saitama Canc Ctr, Med Oncol, Saitama, Japan

[15] Novartis Pharmaceut, Novartis Oncol, E Hanover, NJ USA

[16] Novartis Inst BioMed Res, Biomarkers & Diagnost Biometr, Cambridge, MA USA

[17] Queen Mary Hosp, Med Oncol, Hong Kong, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

10.1093/annonc/mdy428

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

400

引用

页码：13 / +

页数：2

共 50 条

[21] Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis
Bardia, A.
Campos-Gomez, S.
Hurvitz, S. A.
Lu, Y-S.
Im, S-A.
Franke, F.
Chow, L.
Wheatley-Price, P.
Melo Cruz, F.
Alam, J.
Kong, O.
Diaz-Padilla, I.
Miller, M.
Tripathy, D.
ANNALS OF ONCOLOGY, 2018, 29 : 106 - +
[22] Pooled efficacy analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2: Advanced breast cancer (ABC)
Tripathy, D.
Hortobagyi, G. N.
Chan, A.
Im, S-A.
Chia, S.
Yardley, D.
Esteva, F. J.
Hurvitz, S. A.
Ridolfi, A.
Slamon, D.
ANNALS OF ONCOLOGY, 2019, 30 : 49 - +
[23] Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2-mBC): Prevalence, biomarker characteristics, and outcomes.
Jeselsohn, Rinath
Chen, Lu
Chaudhary, Nayan
Martinalbo, Jorge
Fasching, Peter A.
Hafner, Marc
Luhn, Patricia
Montero, Alberto J.
Perez-Moreno, Pablo Diego
Wander, Seth Andrew
Kalinsky, Kevin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] Ribociclib (RIB) plus non-steroidal aromatase inhibitor (NSAI) plus goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study
Im, S-A.
Sohn, J.
Tripathy, D.
Chow, L.
Lee, K. S.
Jung, K. H.
Babu, G.
Im, Y-H.
El Saghir, N.
Liu, M-C.
Diaz-Padilla, I.
Alam, J.
Kong, O.
Miller, M.
Lu, Y-S.
ANNALS OF ONCOLOGY, 2018, 29
[25] HEALTH OUTCOME GAINS AND COSTS OFFSET ASSOCIATED WITH EVEROLIMUS FOR THE TREATMENT OF HORMONE-RECEPTOR-POSITIVE (HR+) HER2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC)
Taylor, M.
Lewis, L.
Vieira, J.
Ricci, J. F.
Chandiwana, D.
Saletan, S.
Sahmoud, T.
VALUE IN HEALTH, 2012, 15 (07) : A427 - A427
[26] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis
Hurvitz, Sara A.
Wheatley-Price, Paul
Tripathy, Debu
Lu, Yen-Shen
Chow, Louis
Bachelot, Thomas Denis
Hegg, Roberto
Chia, Stephen K. L.
Yardley, Denise A.
Kong, Oliver
Alam, Jahangir
Diaz-Padilla, Ivan
Baeck, Johan
Bardia, Aditya
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[27] Ribociclib plus fulvestrant in postmenopausal women with HR+, HER2-advanced breast cancer (ABC)
Tolaney, S. M.
Forero-Torres, A.
Boni, V.
Bachelot, T.
Lu, Y-S
Maur, M.
Fasolo, A.
Motta, M.
Pan, C.
Dobson, J.
Hewes, B.
Lee, S. Chin
CANCER RESEARCH, 2017, 77
[28] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)
Harbeck, N.
Villanueva, R.
Franke, F.
Babu, G.
Wheatley-Price, P.
Im, Y-H.
Altundag, K.
Lanoue, B.
Alam, J.
Chandiwana, D.
Colleoni, M.
ANNALS OF ONCOLOGY, 2018, 29
[29] Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer
Du, Lili
Yau, Christina
Brown-Swigart, Lamorna
Gould, Rebekah
Hirst, Gillian L.
van der Noordaa, Marieke
Bedrosian, Isabelle
Layman, Rachel M.
Valero, Vicente
Van't Veer, Laura
Esserman, Laura
Symmans, W. Fraser
CANCER RESEARCH, 2020, 80 (04)
[30] Ribociclib plus endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations
Julie, Dejan
Campone, Mario
Munster, Pamela
Ismail-Khan, Roohi
Estevez, Laura Garcia
Chavez-MacGregor, Mariana
Frassoldati, Antonio
Hui, Rina
Mayer, Ingrid A.
Cortes, Javier
Goncalves, Anthony
De Boer, Richard H.
Dirix, Luc
Tolaney, Sara M.
Lee, Soo Chin
Maur, Michela
Wang, Yingbo
Su, Faye
Dobson, Jason R.
Germa, Caroline
Hewes, Becker
Bardia, Aditya
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →